Scientists probe why eczema drug works differently across races

NCT ID NCT05268107

Summary

This study aims to understand if the eczema medication dupilumab works the same way in people of different ethnic backgrounds. Researchers will compare the immune system responses of Caucasian, Asian, and African American patients with moderate-to-severe eczema over 16 weeks of treatment. The goal is to learn why some groups are more prone to eczema and if they respond differently to this common therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.